Sarah K Himes1, Yanling Huo, George K Siberry, Paige L Williams, Mabel L Rice, Patricia A Sirois, Toni Frederick, Rohan Hazra, Marilyn A Huestis. 1. *Chemistry and Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD; †Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA; ‡Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD; §Speech, Language, Hearing Department, University of Kansas, Lawrence, KS; ‖Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA; and ¶Department of Research Pediatrics, Maternal, Child, and Adolescent Program for Infectious Diseases and Virology, Keck School of Medicine of USC, Los Angeles, CA.
Abstract
OBJECTIVE: To investigate whether prenatal atazanavir (ATV) exposure, assessed by meconium antiretroviral (ARV) quantification, predicts early child language outcomes. Prenatal ATV exposure previously was associated with poorer language development in 1-year olds. METHODS: Pregnant women with HIV and their uninfected infants enrolled in the Surveillance Monitoring of Antiretroviral Therapy Toxicities study. Meconium ARV concentrations were quantified by liquid chromatography-tandem mass spectrometry. Language development at 1 year was assessed with MacArthur-Bates Communicative Development Inventory (CDI) and Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III). Late language emergence was defined as ≥ 1 of 4 CDI scores ≤ 10th percentile for age. Associations between fetal ATV exposure timing and duration, meconium ATV concentration, and language outcomes were evaluated, adjusting for potential confounders. RESULTS: Through 2013, meconium samples were available from 175 of 432 infants with prenatal ATV exposure. Valid Bayley-III (n = 93) and CDI (n = 106) assessments also were available. After adjustment for potential confounders, higher ATV meconium concentrations were associated with lower late language emergence risk (P = 0.04) and cumulative ATV exposure duration also was associated with higher Bayley-III Language scores (P = 0.03). Maternal ATV duration and initiation week correlated with ATV meconium concentrations (positively and negatively, respectively). CONCLUSIONS: Higher meconium ATV concentrations were protective against developmental language delays at 1 year, suggesting the importance of fetal ATV detoxification into meconium. This information supports ATV exposure safety for infant language development. ATV is a preferred ARV for pregnant women with HIV, suggesting the importance of ATV safety investigations. Additionally, further pursuit of the influences on language development in HIV-exposed uninfected infants is required.
OBJECTIVE: To investigate whether prenatal atazanavir (ATV) exposure, assessed by meconium antiretroviral (ARV) quantification, predicts early child language outcomes. Prenatal ATV exposure previously was associated with poorer language development in 1-year olds. METHODS: Pregnant women with HIV and their uninfected infants enrolled in the Surveillance Monitoring of Antiretroviral Therapy Toxicities study. Meconium ARV concentrations were quantified by liquid chromatography-tandem mass spectrometry. Language development at 1 year was assessed with MacArthur-Bates Communicative Development Inventory (CDI) and Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III). Late language emergence was defined as ≥ 1 of 4 CDI scores ≤ 10th percentile for age. Associations between fetal ATV exposure timing and duration, meconium ATV concentration, and language outcomes were evaluated, adjusting for potential confounders. RESULTS: Through 2013, meconium samples were available from 175 of 432 infants with prenatal ATV exposure. Valid Bayley-III (n = 93) and CDI (n = 106) assessments also were available. After adjustment for potential confounders, higher ATV meconium concentrations were associated with lower late language emergence risk (P = 0.04) and cumulative ATV exposure duration also was associated with higher Bayley-III Language scores (P = 0.03). Maternal ATV duration and initiation week correlated with ATV meconium concentrations (positively and negatively, respectively). CONCLUSIONS: Higher meconium ATV concentrations were protective against developmental language delays at 1 year, suggesting the importance of fetal ATV detoxification into meconium. This information supports ATV exposure safety for infant language development. ATV is a preferred ARV for pregnant women with HIV, suggesting the importance of ATV safety investigations. Additionally, further pursuit of the influences on language development in HIV-exposed uninfected infants is required.
Authors: Stanley Ip; Mei Chung; John Kulig; Rebecca O'Brien; Robert Sege; Stephan Glicken; M Jeffrey Maisels; Joseph Lau Journal: Pediatrics Date: 2004-07 Impact factor: 7.124
Authors: J Steven Leeder; Roger Gaedigk; Kenda A Marcucci; Andrea Gaedigk; Carrie A Vyhlidal; Bradley P Schindel; Robin E Pearce Journal: J Pharmacol Exp Ther Date: 2005-04-21 Impact factor: 4.030
Authors: Sarah K Himes; Karl B Scheidweiler; Katherine Tassiopoulos; Deborah Kacanek; Rohan Hazra; Kenneth Rich; Marilyn A Huestis Journal: Anal Chem Date: 2013-01-14 Impact factor: 6.986
Authors: Sarah K Himes; Laura R Stroud; Karl B Scheidweiler; Raymond S Niaura; Marilyn A Huestis Journal: J Pediatr Date: 2012-12-01 Impact factor: 4.406
Authors: Katherine Tassiopoulos; Yanling Huo; Joseph Braun; Paige L Williams; Renee Smith; Ann Aschengrau; Sharon Nichols; Rohan Hazra; William A Meyer; Katherine Knapp; Nagamah S Deygoo; George R Seage Iii Journal: AIDS Res Hum Retroviruses Date: 2017-03-21 Impact factor: 2.205